Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

January 17, 2024

Study Completion Date

January 17, 2024

Conditions
Electrical Status Epilepticus of Slow-Wave Sleep
Interventions
DRUG

Epidiolex 100 mg/mL Oral Solution

Epidiolex is a schedule 5 controlled substance that is a colorless to yellow oral liquid solution that is prepackaged into 100mL vials with 5mL syringes for use. It is typically used for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet Syndrome in patients 2 years of age and older.

OTHER

Placebo

Placebo is composed of dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose.

Trial Locations (1)

11042

Northwell Health, Lake Success

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

Northwell Health

OTHER